Equities

Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc

Actions
  • Price (EUR)3.80
  • Today's Change-0.12 / -3.06%
  • Shares traded0.00
  • 1 Year change-73.05%
  • Beta--
Data delayed at least 15 minutes, as of Sep 18 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2022202220212020
ASSETS
Cash And Short Term Investments5598103
Total Receivables, Net734151
Total Inventory48228.08
Prepaid expenses12123.72
Other current assets, total------
Total current assets189173166
Property, plant & equipment, net1.171.642.08
Goodwill, net454040
Intangibles, net1181113
Long term investments------
Note receivable - long term------
Other long term assets261017
Total assets406254253
LIABILITIES
Accounts payable19166.27
Accrued expenses623224
Notes payable/short-term debt000
Current portion long-term debt/capital leases6.25268.00
Other current liabilities, total24----
Total current liabilities1117438
Total long term debt56025
Total debt622633
Deferred income tax------
Minority interest------
Other liabilities, total5.302.903.96
Total liabilities1737767
SHAREHOLDERS EQUITY
Common stock0.020.020.02
Additional paid-in capital366326305
Retained earnings (accumulated deficit)1127684
Treasury stock - common(243)(225)(204)
Unrealized gain (loss)------
Other equity, total(1.11)(0.09)--
Total equity234176186
Total liabilities & shareholders' equity406254253
Total common shares outstanding131313
Treasury shares - common primary issue4.554.113.68
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.